Open AccessChanges in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue Sarcoma
Author(s) -
Yasuyoshi Sato,
Kenji Nakano,
Kuniki Kawaguchi,
N. Fukuda,
Xiaofei Wang,
Tetsuya Urasaki,
Akihiro Ohmoto,
Nobuyuki Hayashi,
Mayu Yunokawa,
Makiko Ono,
Junichi Tomomatsu,
Keiko Hayakawa,
Yuki Funauchi,
Taisuke Tanizawa,
Keisuke Ae,
Seiichi Matsumoto,
Shunji Takahashi
Publication year - 2021
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10040
Subject(s) - trabectedin , eribulin , soft tissue sarcoma , medicine , oncology , multivariate analysis , neutrophil to lymphocyte ratio , sarcoma , overall survival , cancer , metastatic breast cancer , breast cancer , pathology
Trabectedin and eribulin are widely used for the treatment of soft-tissue sarcoma (STS). Previously it was shown that the baseline neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of eribulin for STS. However, prognostic factors for trabectedin on STS have not been identified to date.